5-Hydroxytryptamine Receptor 6 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)- Pipeline Review, H2 2019’, provides in depth analysis on 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Respiratory under development targeting 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

– The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects

– The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Adamed Sp zoo

Alla Chem LLC

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

HEC Pharm Co Ltd

Reviva Pharmaceuticals Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Overview

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

Reviva Pharmaceuticals Inc

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Drug Profiles

ADN-1184 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-2013 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-3208 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-211 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-3205 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-322 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-492 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-30654AcOH Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landipirdine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-35700 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-502 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Dormant Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Discontinued Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101

Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders drug candidate SUVN-502 at Neuroscience 2017 at Washington DC

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia

Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s Disease

Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits

Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist

Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events

Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor

Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease

Jul 30, 2014: Biotie updates outlook on SYN120

Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of Treatment of Parkinson's disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Adamed Sp zoo, H2 2019

Pipeline by Alla Chem LLC, H2 2019

Pipeline by Avineuro Pharmaceuticals Inc, H2 2019

Pipeline by Celon Pharma SA, H2 2019

Pipeline by H. Lundbeck AS, H2 2019

Pipeline by HEC Pharm Co Ltd, H2 2019

Pipeline by Reviva Pharmaceuticals Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Dormant Products, H2 2019 (Contd..3), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

`Number of Products by Stage and Mechanism of Actions, H2 2019

`Number of Products by Stage and Route of Administration, H2 2019

`Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports